IDRA-21 Powder

IDRA-21 Powder

Introduction

IDRA-21 Powder is a specialized research compound intended solely for scientific investigation with no connection to human consumption. This formulation provides researchers with a means to study its unique properties and possible effects on memory, focus, and cognition.

Key Characteristics

IDRA-21, a member of the ampakine class, possesses distinct pharmacological characteristics that set it apart. IDRA-21 is known for modulating glutamate receptors and is being studied for its effects on synaptic plasticity and cognitive function.

Research Applications

IDRA-21 Powder is widely used in research to study its potential effects on memory, focus, and cognition.

Research Benefits

IDRA-21’s Role in Memory and Focus

Studies suggest that IDRA-21 may have a positive impact on memory and focus by modulating glutamate receptors, potentially enhancing synaptic plasticity. Research aims to explore its possible role in cognitive performance.

IDRA-21 and Overall Cognition

Preliminary research indicates that IDRA-21 may influence overall cognition through its effects on glutamate receptors. Studies on its cognitive effects help clarify its role in cognitive enhancement research (Reference 2).

Summary

IDRA-21 Powder is designed solely for research, offering a way to study its effects on memory, focus, and cognition. The distinctive characteristics of IDRA-21 make it a promising subject for further exploration in neuroscience and cognitive research.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions.  Customer contentment stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at support@bc9.co.

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Thompson DM, Guidotti A, DiBella M, Costa E. 7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S, S-dioxide (IDRA 21), a congener of aniracetam, potently abates pharmacologically induced cognitive impairments in patas monkeys. Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7667-71. doi: 10.1073/pnas.92.17.7667. PMID: 7644474; PMCID: PMC41206. [Read More].
2. Purves D, Augustine GJ, Fitzpatrick D, et al., editors. Neuroscience. 2nd edition. Sunderland (MA): Sinauer Associates; 2001. Long-Term Synaptic Potentiation. Available from: https://www.ncbi.nlm.nih.gov/books/NBK10878/ [Read More].